Compare LMND & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | APGE |
|---|---|---|
| Founded | 2015 | 2022 |
| Country | United States | United States |
| Employees | 1282 | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 4.7B |
| IPO Year | N/A | 2023 |
| Metric | LMND | APGE |
|---|---|---|
| Price | $57.50 | $81.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $70.86 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 1.6M | 556.4K |
| Earning Date | 04-29-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $65.20 | N/A |
| Revenue Next Year | $33.31 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.50 | $34.34 |
| 52 Week High | $99.90 | $95.32 |
| Indicator | LMND | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 49.84 | 46.42 |
| Support Level | $52.26 | $80.52 |
| Resistance Level | $58.56 | $86.42 |
| Average True Range (ATR) | 2.81 | 3.93 |
| MACD | 0.32 | -0.55 |
| Stochastic Oscillator | 88.66 | 46.23 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. The Company operates in one report segment providing personal property and casualty insurance products within the United States and Europe, including the UK.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.